Study of AMG 160 in Subjects With Non-Small Cell Lung Cancer

Phase 1 Terminated 3 enrolled Amgen

Non-randomizedSequentialOpen-labelTreatment

Summary

This study aims to evaluate the safety and tolerability of AMG 160 and to evaluate the maximum tolerated dose (MTD) or the recommended phase 2 dose (RP2D).

Timeline

Start: 2021-08-31
Primary completion: 2021-12-08
Completion: 2022-01-26

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Acapatamab	Monoclonal antibody	—	Intravenous

Study of AMG 160 in Subjects With Non-Small Cell Lung Cancer

Summary

Timeline

Drugs

Indications